ReviewCritical reviews in oncology/hematology2020
Coronavirus infection and immune system: An insight of COVID-19 in cancer patients.
Review in Critical reviews in oncology/hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- The Rise of Wearable Devices during the COVID-19 Pandemic: A Systematic Review.Sensors (Basel, Switzerland) · 2021Pooled it
- Noncoding RNA (ncRNA)-mediated regulation of TLRs: critical regulator of inflammation in tumor microenvironment.Medical oncology (Northwood, London, England) · 2025Review
- Characteristics and specifications of dashboards developed for the COVID-19 pandemic: a scoping review.Zeitschrift fur Gesundheitswissenschaften = Journal of public health · 2023Review
- Association between the overall burden of comorbidity and Ct values among the older patients with Omicron infection: Mediated by inflammation.Frontiers in immunology · 2023Observational
- Global Effect of COVID-19 Pandemic on Cancer Patients and its Treatment: A Systematic Review.Clinical complementary medicine and pharmacology · 2022Review
- Health influence of SARS-CoV-2 (COVID-19) on cancer: a review.Acta biochimica et biophysica Sinica · 2022Review
- Recurrent viral RNA positivity and candidiasis findings in hospitalized patients with COVID-19.Future microbiology · 2022Article
- The Importance of Nutraceuticals in COVID-19: What's the Role of Resveratrol?Molecules (Basel, Switzerland) · 2022Review
- COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.Frontiers in immunology · 2022Review
- Routine COVID-19 testing may not be necessary for most cancer patients.Scientific reports · 2021Article
- Interaction of the inflammatory response and megakaryocytes in COVID-19 infection.Experimental hematology · 2021Review
- Surgical oncology operative experience at a high-volume safety-net hospital during the COVID-19 pandemic.Journal of surgical oncology · 2021Article
- Global dynamics of SARS-CoV-2/cancer model with immune responses.Applied mathematics and computation · 2021Article
- Modelling COVID-19 severity in the Republic of Ireland using patient co-morbidities, socioeconomic profile and geographic location, February to November 2020.Scientific reports · 2021Article
- Article
- An approach of fatty acids and resveratrol in the prevention of COVID-19 severity.Phytotherapy research : PTR · 2021Article
- A case series of children and young people admitted to a tertiary care hospital in Germany with COVID-19.BMC infectious diseases · 2021Observational
- Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.Frontiers in immunology · 2021Article
- Impact of COVID-19 Pandemic on Ovarian Cancer Management: Adjusting to the New Normal.Cancer management and research · 2021Review
- Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus respiratory illness (COVID-19) is a public health emergency of global concern. Patients with cancer are at high risk of infections, due to an overall immunocompromised status. However, this connection is not straightforward for coronavirus (CoV) infection, in which the host immune response is the main driver of tissue damage. We performed a thorough review of data on CoV pathogenesis and morbidity rate in cancer patients, through the analysis of the previous CoV pandemics. Considering the interaction between CoV and the host immune system, cancer patients receiving immunotherapy might be more at risk for an aberrant immune response in case of infection, and might therefore deserve additional precautions. The limited available data do not allow us to provide practical indications for the management of cancer patients in this critical situation. Efforts should be made to prospectively collect data, to identify effective interventions to guide treatment decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.